- The 2019 Fall CMTA ReportThe Type 2 Issue: We have set the stage for a number of Type 2 breakthroughs on our way to treatments for CMT.Read more ...
- New Gene Therapy, Type 1/Type 4 Research Projects ApprovedThe CMTA today announced another $335,000 in grants to top CMT scientists leading the field in CMT Type 1 research. The grants cover work on types 1A, 1B and 1X and other demyelinating forms of CMT, including type 4.Read more ...
- New Gene Therapy Development Program for CMT2APassage Bio, a genetic medicines company developing AAV-delivered gene therapies, today announced a gene therapy development program for Charcot-Marie-Tooth Neuropathy Type 2A (CMT2A).Read more ...
- $1 Million Gift Pledged to CMT Type 2 Research!Bob and Gail Buuck are big believers in “impact giving,” They have pledged a $1 million gift to advance CMT Type 2 research.Read more ...
- 2019 Summer CMTA ReportAll in the Family: The many branches of the CMTA family tree—the patients, the families that support them and the doctors who treat them.Read more ...